Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Tested positive again for Covid one week after finishing paxlovid and testing negative; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive again for Covid one week after finishing paxlovid and testing negative) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Q48L21A) for COVID-19 vaccination.     The patient did not had relevant medical history and concurrent conditions.  Concurrent medical conditions included Drug allergy. Concomitant products included EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE (SYNJARDY) for an unknown indication.    On 06-Apr-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2022 at 12:15 PM, the patient experienced COVID-19 (Tested positive again for Covid one week after finishing paxlovid and testing negative). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 02-May-2022 to 06-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Tested positive again for Covid one week after finishing paxlovid and testing negative) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-May-2022, SARS-CoV-2 test: positive (Positive) Positive. In May 2022, SARS-CoV-2 test: negative (Negative) Negative.         Patient tested positive again for Covid one week after finishing packovid and testing negative. Device Date was reported as 13-May-2022.  Company Comment: This spontaneous case concerns a 61 year old female patient with no relevant medical history reported  , who experienced Non-serious , unexpected , AESI of Covid 19 which occurred one month seven  days post vaccination with the 4th dose of mRNA-1273 vaccine. The details regarding the dose 1, 2 3 Covid 19 vaccine of this patient was not reported. This patient received treatment of  NIRMATRELVIR, RITONAVIR (PAXLOVID) from 02-May-2022 to 06-May-2022 for COVID-19 treatment at an unspecified dose and frequency . And it was reported that this patient Tested positive AGAIN for Covid one week after the treatment. Symptoms of Covid 19 was not reported at the time that she  turned out to be positive again.  Other treatment information , results of other laboratories like RT-PCR or viral culture results/diagnostic procedures were not reported including if any medical consultation was done. Outcome of the event was reported as not resolved. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This spontaneous case concerns a 61 year old female patient with no relevant medical history reported  , who experienced Non-serious , unexpected , AESI of Covid 19 which occurred one month seven  days post vaccination with the 4th dose of mRNA-1273 vaccine. The details regarding the dose 1, 2 3 Covid 19 vaccine of this patient was not reported. This patient received treatment of  NIRMATRELVIR, RITONAVIR (PAXLOVID) from 02-May-2022 to 06-May-2022 for COVID-19 treatment at an unspecified dose and frequency . And it was reported that this patient Tested positive AGAIN for Covid one week after the treatment. Symptoms of Covid 19 was not reported at the time that she  turned out to be positive again.  Other treatment information , results of other laboratories like RT-PCR or viral culture results/diagnostic procedures were not reported including if any medical consultation was done. Outcome of the event was not resolved. . The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.